GlassScriptPhysician profile
Nathaniel M Schuster
NPI 1861781205
$336,581.96
in general payments reported to CMS, 2019-2025
29 companies · $26K in 2025
The $26K reported for 2025 was more than what 98% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $42K · 2021: $50K · 2022: $65K · 2023: $97K · 2024: $25K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $70K · Honoraria: $43K · Travel and Lodging: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,233 · Food and Beverage: $3,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $70,315.00 |
| Honoraria | $43,245.00 |
| Travel and Lodging | $25,496.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,232.50 |
| Food and Beverage | $3,667.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $123,181.13 | 2019-2023 | Reyvow, Emgality |
| Averitas Pharma INC. | $63,032.73 | 2023-2024 | Qutenza |
| Grt US Holding, INC. | $58,749.16 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $58,350.00 | 2023 | Xtampza, Belbuca, Nucynta |
| Vertex Pharmaceuticals Incorporated | $17,498.26 | 2025 | |
| H. Lundbeck A S | $6,023.03 | 2025 | Vyepti |
| Eli Lilly and Company | $3,000.00 | 2021 | |
| Axsome Therapeutics, INC. | $1,853.15 | 2025 | Symbravo |
| Lundbeck LLC | $1,750.00 | 2020 | |
| Boston Scientific Corporation | $691.92 | 2019-2025 | Intracept |
| Spr Therapeutics, INC | $397.99 | 2019-2024 | Sprint Pns System |
| Allergan, INC. | $393.33 | 2020 | |
| Nevro Corp. | $368.90 | 2019-2022 | |
| Abbott Laboratories | $160.73 | 2024-2025 | Eterna |
| Merz Pharmaceuticals, LLC | $159.05 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $152.91 | 2021-2023 | Intellis Adaptivestim, Accurian |
| Spinal Simplicity, LLC | $126.72 | 2021 | |
| Pfizer INC. | $124.77 | 2025 | |
| Vertos Medical, INC. | $124.43 | 2023 | Mild Device Kit |
| Scilex Pharmaceuticals INC. | $112.70 | 2025 | |
| Abbvie INC. | $91.26 | 2023 | Botox |
| Avanos Medical | $77.92 | 2021-2022 | |
| Tonix Medicines, INC. | $77.10 | 2025 | |
| Relievant Medsystems, INC. | $40.48 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.94 | 2021 | |
| Nalu Medical, INC. | $16.39 | 2020 | |
| Tenex Health INC. | $10.96 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Schuster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.